Houston Methodist. Leading Medicine

Hand News

The Fate of Dupuytren's Nodules: A Six-Year Follow-Up Study

In this study researchers at the University of Cincinnati followed 59 patients with Dupuytren's nodules of the hand. Patients were seen for at least six years from the time symptoms started.

Dupuytren's involves the fascia or connective tissue of the palm. An excess of abnormal connective tissue forms nodules in the palm. The base of the ring and little fingers are affected most often.

The authors review the course of the disease. Nodules form then develop into cords. Joint contractures form with loss of motion. As time goes on the condition usually gets worse and often affects both hands. A small number of patients do get better.

The authors found three major risk factors in how quickly Dupuytren's progresses. These include disease before age 50, Northern European ethnicity, and a positive family history of Dupuytren's.

The overall fate of most patients with Dupuytren's is one of gradual progression. The earlier it develops in life, the faster it gets worse. Surgery to remove the nodules is not always advised. Often the nodules come back.

Rachel M. Reilly, BS, et al. A Retrospective Review of the Management of Dupuytren's Nodules. In The Journal of Hand Surgery. September 2005. Vol. 30A. No. 5. pp. 1014-1018.


*Disclaimer:* The information contained herein is compiled from a variety of sources. It may not be complete or timely. It does not cover all diseases, physical conditions, ailments or treatments. The information should NOT be used in place of visit with your healthcare provider, nor should you disregard the advice of your health care provider because of any information you read in this topic.
All content provided by eORTHOPOD® is a registered trademark of Medical Multimedia Group, L.L.C.. Content is the sole property of Medical Multimedia Group, LLC and used herein by permission.

Our Specialties

Where Does It Hurt?

Our Locations

  Follow Us

Follow us on Facebook Follow us on YouTube
Follow us on Twitter